FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293539> ?p ?o ?g. }

• W4286293539 endingPage "4570" @default.
• W4286293539 startingPage "4570" @default.
• W4286293539 abstract "4570 Background: Overexpression of HER-2 is associated with poor prognosis of urothelial cancer, and anti-HER-2 antibody-drug conjugate (ADC) has shown a promising efficacy among the UC patients (pts) in recently studies. MRG002 is a novel HER2-targeted ADC being investigated in the MRG002-006 trial to evaluate the efficacy and safety in HER2 positive UC pts. Methods: This is a single-arm, multicenter phase II study. Eligibility criteria included: histologically HER2-positive (IHC 2+ or 3+) UC pts confirmed by a central-laboratory, ECOG PS 0-1, prior received ≥1 standard treatment. Approximately 40 pts will be enrolled. In the initial dose finding stage, pts were assigned to receive MRG002 at a dose of 2.6 mg/kg or 2.2 mg/kg administered by intravenous infusion every 3 weeks. The dose expanding stage was subsequentially performed based on preliminary results. The primary endpoint was ORR per RECIST 1.1, secondary endpoints are safety, DOR, PFS and, OS. Results: As of December 31, 2021, a total of 39 pts were enrolled. Enrollment is estimated be completed in February 28, 2022, and results are expected to be updated before publication. Nine pts were dosed at 2.6 mg/kg and 26 pts were dosed at 2.2 mg/kg. Based on safety analysis, 2.2 mg/kg was adopted as the recommended dosage. At baseline, 80% pts (28/35) had visceral metastasis. Most pts (28/35) received ≥ 2 lines of treatment and 29 (83%) pts had prior immune checkpoint inhibitor (ICI) therapy. By the cut-off date, 23 pts were evaluable and the ORR was 65% (15/23, 95% CI: 44.9%–81.2%), with 9% CR, and the DCR was 91% (21/23, 95% CI: 73.2%–97.6%). The estimated median PFS for the 23 pts was 5.5 months (95% CI: 2.7–NR). Among the evaluable pts, 1 CR responder achieved a response duration of more than 9.5 months. Subgroup analysis indicated that the ORR was 65% among the 17 pts post ≥ 2 lines of treatment, and 78% among the 18 pts failed platinum-containing chemotherapy and ICI treatment. Most common treatment-related AEs determined by investigators were anemia (34%), alopecia (34%), AST increased (31%), neutrophil count decreased (26%), neuropathy peripheral (23%), constipation (17%), decreased appetite (17%); most were grade 1 or 2 per CTCAE 5.0. The incidence of SAE was 17% (6/35). At the dose of 2.6mg/kg, 1 pts discontinued the treatment due to hypotension and 1 pts experienced ileus, which was considered caused by neurotoxicity of MRG002. There were no similar events described above happened among the pts at the dose of 2.2mg/kg. Conclusions: Preliminary results of MRG002 demonstrated a clinically meaningful response in pretreated HER-2 positive unresectable locally advanced or metastatic UC patients, especially in those progressed after platinum-containing chemotherapy and ICI therapy. MRG002 at 2.2mg/kg showed a manageable safety profile in these pts. Further evaluation is ongoing. Clinical trial information: NCT04839510." @default.
• W4286293539 created "2022-07-21" @default.
• W4286293539 creator A5011955138 @default.
• W4286293539 creator A5012162881 @default.
• W4286293539 creator A5019633331 @default.
• W4286293539 creator A5021273060 @default.
• W4286293539 creator A5021449354 @default.
• W4286293539 creator A5021602427 @default.
• W4286293539 creator A5031103557 @default.
• W4286293539 creator A5039089554 @default.
• W4286293539 creator A5040715442 @default.
• W4286293539 creator A5048295407 @default.
• W4286293539 creator A5049541670 @default.
• W4286293539 creator A5050445168 @default.
• W4286293539 creator A5053329617 @default.
• W4286293539 creator A5055954755 @default.
• W4286293539 creator A5056930997 @default.
• W4286293539 creator A5075941332 @default.
• W4286293539 creator A5081420340 @default.
• W4286293539 creator A5085403638 @default.
• W4286293539 creator A5087014003 @default.
• W4286293539 creator A5088203524 @default.
• W4286293539 date "2022-06-01" @default.
• W4286293539 modified "2023-10-01" @default.
• W4286293539 title "MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer." @default.
• W4286293539 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4570" @default.
• W4286293539 hasPublicationYear "2022" @default.
• W4286293539 type Work @default.
• W4286293539 citedByCount "3" @default.
• W4286293539 countsByYear W42862935392022 @default.
• W4286293539 countsByYear W42862935392023 @default.
• W4286293539 crossrefType "journal-article" @default.
• W4286293539 hasAuthorship W4286293539A5011955138 @default.
• W4286293539 hasAuthorship W4286293539A5012162881 @default.
• W4286293539 hasAuthorship W4286293539A5019633331 @default.
• W4286293539 hasAuthorship W4286293539A5021273060 @default.
• W4286293539 hasAuthorship W4286293539A5021449354 @default.
• W4286293539 hasAuthorship W4286293539A5021602427 @default.
• W4286293539 hasAuthorship W4286293539A5031103557 @default.
• W4286293539 hasAuthorship W4286293539A5039089554 @default.
• W4286293539 hasAuthorship W4286293539A5040715442 @default.
• W4286293539 hasAuthorship W4286293539A5048295407 @default.
• W4286293539 hasAuthorship W4286293539A5049541670 @default.
• W4286293539 hasAuthorship W4286293539A5050445168 @default.
• W4286293539 hasAuthorship W4286293539A5053329617 @default.
• W4286293539 hasAuthorship W4286293539A5055954755 @default.
• W4286293539 hasAuthorship W4286293539A5056930997 @default.
• W4286293539 hasAuthorship W4286293539A5075941332 @default.
• W4286293539 hasAuthorship W4286293539A5081420340 @default.
• W4286293539 hasAuthorship W4286293539A5085403638 @default.
• W4286293539 hasAuthorship W4286293539A5087014003 @default.
• W4286293539 hasAuthorship W4286293539A5088203524 @default.
• W4286293539 hasConcept C121608353 @default.
• W4286293539 hasConcept C126322002 @default.
• W4286293539 hasConcept C126894567 @default.
• W4286293539 hasConcept C141071460 @default.
• W4286293539 hasConcept C143998085 @default.
• W4286293539 hasConcept C146357865 @default.
• W4286293539 hasConcept C151730666 @default.
• W4286293539 hasConcept C203092338 @default.
• W4286293539 hasConcept C2779984678 @default.
• W4286293539 hasConcept C2780352672 @default.
• W4286293539 hasConcept C3020745361 @default.
• W4286293539 hasConcept C31760486 @default.
• W4286293539 hasConcept C535046627 @default.
• W4286293539 hasConcept C71924100 @default.
• W4286293539 hasConcept C86803240 @default.
• W4286293539 hasConcept C90924648 @default.
• W4286293539 hasConceptScore W4286293539C121608353 @default.
• W4286293539 hasConceptScore W4286293539C126322002 @default.
• W4286293539 hasConceptScore W4286293539C126894567 @default.
• W4286293539 hasConceptScore W4286293539C141071460 @default.
• W4286293539 hasConceptScore W4286293539C143998085 @default.
• W4286293539 hasConceptScore W4286293539C146357865 @default.
• W4286293539 hasConceptScore W4286293539C151730666 @default.
• W4286293539 hasConceptScore W4286293539C203092338 @default.
• W4286293539 hasConceptScore W4286293539C2779984678 @default.
• W4286293539 hasConceptScore W4286293539C2780352672 @default.
• W4286293539 hasConceptScore W4286293539C3020745361 @default.
• W4286293539 hasConceptScore W4286293539C31760486 @default.
• W4286293539 hasConceptScore W4286293539C535046627 @default.
• W4286293539 hasConceptScore W4286293539C71924100 @default.
• W4286293539 hasConceptScore W4286293539C86803240 @default.
• W4286293539 hasConceptScore W4286293539C90924648 @default.
• W4286293539 hasIssue "16_suppl" @default.
• W4286293539 hasLocation W42862935391 @default.
• W4286293539 hasOpenAccess W4286293539 @default.
• W4286293539 hasPrimaryLocation W42862935391 @default.
• W4286293539 hasRelatedWork W2058763863 @default.
• W4286293539 hasRelatedWork W2152756917 @default.
• W4286293539 hasRelatedWork W2760661635 @default.
• W4286293539 hasRelatedWork W2921414657 @default.
• W4286293539 hasRelatedWork W2936810997 @default.
• W4286293539 hasRelatedWork W3177224496 @default.
• W4286293539 hasRelatedWork W4286293539 @default.
• W4286293539 hasRelatedWork W4304690509 @default.
• W4286293539 hasRelatedWork W4306253774 @default.
• W4286293539 hasRelatedWork W4313545978 @default.

• next